Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Software Development

14 Feb 2008 07:01

Angle PLC14 February 2008 For Immediate Release 14 February 2008 ANGLE plc Software Development Kit Launched by Geomerics ANGLE plc is pleased to announce that its venture company Geomerics hascompleted its Software Development Kit (SDK) for Enlighten, the revolutionaryradiosity lighting engine for PLAYSTATION(R)3, the Xbox 360(TM) entertainmentsystem from Microsoft and PC. Enlighten's SDK comprises a modular toolkit withan emphasis on easy integration into existing development frameworks. It alsoboasts intuitive operation designed with artists in mind and full support forindustry standard packages such as 3D Studio Max and Maya for maximumoperability. Enlighten's radiosity solution represents a generational step in videogamegraphics technology, surpassing all currently popular lighting techniques.Radiosity is the ability to model light as it bounces from surfaces and it iskey to generating high quality visual images. Current technologies forgenerating radiosity lighting involve either pre-computing it in advance, orfaking it with multiple hidden lights. These methods are typically inflexible,time-consuming and often generate poor results. Enlighten computes full multiple-bounce radiosity at runtime, giving developersthe quality of pre-computed lighting without the pre-compute. In-game lightingcan also be fully dynamic, giving designers a powerful new tool with hugepotential for enhancing the atmosphere and mood of any scene. Additionally,Enlighten's instantaneous feedback means that artists are freed up to experimentwith light, shadow and colour in dramatic new ways - just as if they were usingreal lights on a studio set. Gary Lewis, CEO, Geomerics comments: "We are delighted to be announcing the launch of the Enlighten SDK. With our SDKcompleted, we are looking forward to seeing Enlighten gaining the support itdeserves within the games industry. We are certain that once developers gettheir hands on the SDK and experiment with it for themselves, they will see thetrue power and versatility of Enlighten and the huge potential it has forrevolutionising the look of videogames for years to come." Geomerics will be at Expo Suite 561 throughout GDC Expo 2008, which runs from20th to the 22nd February. To book a meeting please contact: info@geomerics.com Enlighten is available for licensing for PC, Xbox 360 and Playstation 3. Formore information please contact: sales@geomerics.com Enquiries: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Angle plc Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE has a 48% equity holding in Geomerics Ltd.ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com Geomerics Ltd Geomerics is an innovation-led company specialising in graphics software for thegames industry and beyond. It is built on a combination of advanced in-house IP,a remarkable research team, and strong management experience. The company'sfirst product is Enlighten. Enlighten radically transforms the way that lightingis handled in computer games. Instead of pre-baking the effects of globalillumination into the scene they can now be computed at run time, allowing forfully dynamic lighting. This dramatically enhances realism as well as opening upa new world of creative possibilities for designers and artists. Further information can be found on www.geomerics.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.